• 1. Department of Respiratory and Critical Care Medicine, Jintang First People’s Hospital / Jintang Hospital, West China Hospital, Sichuan University, Chengdu, Sichuan 610400, P. R. China;
  • 2. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
LUO Fengming, Email: 790847157@qq.com
Export PDF Favorites Scan Get Citation

Interstitial lung disease is the most common pulmonary complication in patients with inflammatory myopathy, with a high case fatality rate, unknown pathogenesis, and complex clinical manifestations, and the treatment is difficult. Early and timely treatment can improve the patient’s clinical symptoms and inhibit the development of the disease. The present treatment protocols can be mainly summarized as the commonly used drugs (corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, and intravenous immunoglobulin) and new drugs (cyclosporin A, tacrolimus, biological agents, and anti-fibrosis drug), etc. In this paper, the treatment progress of inflammatory myopathy-related interstitial lung disease and different myositis antibody-related interstitial lung disease in recent years at home and abroad is reviewed, so as to provide a basis for clinical treatment.

Citation: LI Jing, LUO Fengming. Treatment progress of interstitial lung disease with idiopathic inflammatory myopathies. West China Medical Journal, 2021, 36(1): 114-119. doi: 10.7507/1002-0179.201909140 Copy

  • Previous Article

    Research progress on biomarkers of pulmonary lymphangioleiomyomatosis
  • Next Article

    Progress in diagnosis and treatment of interstitial lung disease in patients with melanoma differentiation-associated gene 5 antibody-positive dermatomyositis